→
The analysis indicates that investors should consider both growth potential and competitive challenges when evaluating Merck's performance.
Merck & Co., Inc. has a market cap of $376.88B and a current price of $150.33, reflecting a decrease of 1.31% from the previous close of $152.33. The P/E ratio stands at 20.65, with a P/S ratio of 5.80 and a P/B ratio of 7.16. The company reports an EPS growth of 8.01% year-over-year, while revenue growth is at 1.31%. The dividend yield is 2.17%.
Some investors cite Merck's strong ROE of 34.70% and its consistent EPS growth of 8.01% year-over-year as indicators of robust operational efficiency. Additionally, the successful development of innovative treatments, like the potential oral PCSK9 pill, could enhance revenue streams.
Conversely, concerns about Merck's recent revenue growth of only 1.31% year-over-year and its significant competition in the oncology space, evidenced by reports of competing products like those from Summit Therapeutics, could impact future market share. The recent dip in stock price also suggests market apprehension.
Want AI analysis of your entire portfolio?
Helm Terminal connects to your brokerage, analyzes every holding, and delivers actionable intelligence weekly. Free to start.
Get started freeHelm provides financial data for informational purposes only. This is not financial, investment, or tax advice. Consult a qualified professional before making financial decisions.
Watch my tickers
Get an email when something changes on your tickers: the exact quote, dated and sourced. No account, no brokerage connection, unsubscribe anytime.
Merck & Co., Inc. has a market cap of $376.88B and a current price of $150.33, reflecting a decrease of 1.31% from the previous close of $152.33. The P/E ratio stands at 20.65, with a P/S ratio of 5.80 and a P/B ratio of 7.16. The company reports an EPS growth of 8.01% year-over-year, while revenue growth is at 1.31%. The dividend yield is 2.17%.
Conversely, concerns about Merck's recent revenue growth of only 1.31% year-over-year and its significant competition in the oncology space, evidenced by reports of competing products like those from Summit Therapeutics, could impact future market share. The recent dip in stock price also suggests market apprehension.
Some investors cite Merck's strong ROE of 34.70% and its consistent EPS growth of 8.01% year-over-year as indicators of robust operational efficiency. Additionally, the successful development of innovative treatments, like the potential oral PCSK9 pill, could enhance revenue streams.
Some investors cite Merck's strong ROE of 34.70% and its consistent EPS growth of 8.01% year-over-year as indicators of robust operational efficiency. Additionally, the successful development of innovative treatments, like the potential oral PCSK9 pill, could enhance revenue streams. Conversely, concerns about Merck's recent revenue growth of only 1.31% year-over-year and its significant competition in the oncology space, evidenced by reports of competing products like those from Summit Therapeutics, could impact future market share. The recent dip in stock price also suggests market apprehension.
Merck & Co., Inc. has a market cap of $376.88B and a current price of $150.33, reflecting a decrease of 1.31% from the previous close of $152.33. The P/E ratio stands at 20.65, with a P/S ratio of 5.80 and a P/B ratio of 7.16. The company reports an EPS growth of 8.01% year-over-year, while revenue growth is at 1.31%. The dividend yield is 2.17%.
Helm's analysis is generated by an AI model from live market data. It identifies risk signals, opportunities, and key metrics based on current fundamentals, recent price action, and analyst consensus. It does not execute trades, issue certified investment advice, or predict future prices.
Not financial advice. Informational use only. AI-generated content may contain errors. Consult a licensed financial advisor before making investment decisions. Helm Terminal is not registered as an investment advisor.
Helm Terminal offers free AI-powered stock analysis for MRK at helmterminal.dev/analyze/MRK, updated continuously during US market hours. No signup required.